These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 28407394)

  • 21. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.
    Wang CC; Lee CL; Kuo HC
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
    Herschorn S; Kohan A; Aliotta P; McCammon K; Sriram R; Abrams S; Lam W; Everaert K
    J Urol; 2017 Jul; 198(1):167-175. PubMed ID: 28161352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC; Kuo HC
    Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
    Sherif H; Khalil M; Omar R
    Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
    Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
    Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.
    Jo JK; Kim KN; Kim DW; Kim YT; Kim JY; Kim JY
    World J Urol; 2018 Feb; 36(2):305-317. PubMed ID: 29124347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.
    Dowson C; Watkins J; Khan MS; Dasgupta P; Sahai A
    Eur Urol; 2012 Apr; 61(4):834-9. PubMed ID: 22204745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin as a treatment for refractory overactive bladder.
    Harris S; Rizzolo D
    JAAPA; 2016 Feb; 29(2):1-4. PubMed ID: 26818640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
    Ginsberg D; Cruz F; Herschorn S; Gousse A; Keppenne V; Aliotta P; Sievert KD; Brin MF; Jenkins B; Thompson C; Lam W; Heesakkers J; Haag-Molkenteller C
    Adv Ther; 2013 Sep; 30(9):819-33. PubMed ID: 24072665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.
    Denys P; Le Normand L; Ghout I; Costa P; Chartier-Kastler E; Grise P; Hermieu JF; Amarenco G; Karsenty G; Saussine C; Barbot F;
    Eur Urol; 2012 Mar; 61(3):520-9. PubMed ID: 22036776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
    Kuo HC; Liu HT; Chuang YC; Birder LA; Chancellor MB
    Eur Urol; 2014 Jun; 65(6):1117-24. PubMed ID: 24555904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of a study examining the use of onabotulinumtoxinA in pediatric patients with overactive bladder.
    Hoebeke P; Hittelman A; Jenkins B; Geib T; Titanji W; Bogaert G
    J Pediatr Urol; 2024 Aug; 20(4):600.e1-600.e8. PubMed ID: 38906707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.
    Lahdes-Vasama TT; Anttila A; Wahl E; Taskinen S
    Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective randomized clinical trial comparing two doses of AbobotulinumtoxinA for idiopathic overactive bladder.
    de Sá Dantas Bezerra D; de Toledo LGM; da Silva Carramão S; Silva Rodrigues AF; Dmockowski R; Auge APF
    Neurourol Urodyn; 2019 Feb; 38(2):660-667. PubMed ID: 30525226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease.
    Vurture G; Peyronnet B; Feigin A; Biagioni MC; Gilbert R; Rosenblum N; Frucht S; Di Rocco A; Nitti VW; Brucker BM
    Neurourol Urodyn; 2018 Nov; 37(8):2669-2677. PubMed ID: 29767449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.